Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and growth-oriented investments and capital allocation.
Greg Rodetis; Senior Vice President, Treasurer and Head of Investor Relations; Becton Dickinson and Co Thomas Polen; Chairman of the Board, President, Chief Executive Officer; Becton Dickinson and Co ...
At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...
U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of ...
Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.
Becton Dickinson (BDX) stock slid 3% after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate entities.
Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.
BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...
Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $3.43 in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback